Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016


#739374

67pages

Global Markets Direct

$ 2000

In Stock

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016

Summary

Global Markets Directs, Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC)
- The report reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Muscle Invasive Bladder Cancer (MIBC) therapeutics and enlists all their major and minor projects
- The report assesses Muscle Invasive Bladder Cancer (MIBC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Muscle Invasive Bladder Cancer (MIBC) Overview 7
Therapeutics Development 8
Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview 8
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies 9
Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies 13
Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development 14
Astellas Pharma Inc. 14
Cold Genesys, Inc. 15
F. Hoffmann-La Roche Ltd. 16
Oncolytics Biotech Inc. 17
Taris Biomedical LLC 18
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
atezolizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CG-0070IT - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
erlotinib hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
gemcitabine hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pelareorep - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Muscle Invasive Bladder Cancer (MIBC) - Recent Pipeline Updates 45
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects 64
Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones 65
Featured News & Press Releases 65
Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc., H1 2016 14
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys, Inc., H1 2016 15
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc., H1 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Muscle Invasive Bladder Cancer (MIBC) Therapeutics - Recent Pipeline Updates, H1 2016 45
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H1 2016 64

List of Figures
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26

NA

NA